AccessibilityHelp
Theralase Technologies logo

Theralase Technologies(OTC) TLTFF

Market Cap$45.24MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2012)-22%
5 Year-15%
1 Year-6%
1 Month+19%
$0.15
-2.67%
-0.00Today
Theralase Technologies last closing stock price
MetricPriceDate
Last closeUSD 0.152026-10-23
Theralase Technologies stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+7.93%USD 0.142026-10-16
1 month+18.92%USD 0.122026-09-23
3 month-22.54%USD 0.192026-07-24
Year to date+23.32%USD 0.122025-12-31
1 year-6.3%USD 0.162025-10-23
3 year-2.48%USD 0.152023-10-24
5 year-14.6%USD 0.172021-10-22
Since inception-22.09%USD 0.192012-07-13

Theralase Technologies Financials at a Glance

Market Cap

$45.24MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

CA$802.80K

Net Income (TTM)

-CA$3.79M

EPS (TTM)

-$0.01

P/E Ratio

-14.15

Dividend

$0.00

Beta (Volatility)

0.70 (Low)

Price

$0.15

Volume

178,565

Open

$0.16

Previous Close

$0.15

Daily Range

$0.15 - $0.18

52-Week Range

$0.10 - $0.31

Estimated Earnings Date

Nov 10, 2026

TLTFF News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Theralase Technologies

Theralase Technologies Inc. is a clinical-stage pharmaceutical company based in Toronto, Canada, focused on developing innovative therapies and medical devices. The company specializes in photodynamic compounds (PDCs) aimed at treating cancer, bacterial infections, and viral diseases, while also offering advanced laser technology for pain management.

Products and Services
  • Photodynamic compounds for cancer and infection treatment
  • Super-pulsed laser technology for chronic pain relief
  • Controller-less cool laser therapy systems for various conditions
Growth Outlook
  • Significant drug candidate TLD-1433 in Phase II trials for bladder cancer
  • Research agreements for developing coronavirus vaccines and therapies
  • Expansion of laser technology applications in healthcare settings
Financial Highlights
  • Recent quarterly revenue of CAD 164,293, showing growth potential
  • Cash and short-term investments of CAD 5,260,832 as of June 30, 2026
  • Current ratio of 5.48 indicates strong liquidity position
Theralase Technologies Inc. operates in the medical devices sector, with a focus on innovative solutions that address significant health challenges. The company is advancing its drug pipeline, particularly with TLD-1433, which targets a critical area in cancer treatment. Collaborations with academic institutions and health agencies further enhance its research capabilities, particularly in the context of emerging health threats like COVID-19. The financial position reflects a commitment to research and development, with substantial investments in R&D expenses. The recent quarterly revenue indicates a positive trajectory, while the strong liquidity position suggests that the company is well-equipped to navigate its clinical trials and operational needs. Overall, Theralase Technologies Inc. presents a compelling opportunity for investors interested in the intersection of healthcare innovation and market growth.
AI Generated • Oct 15, 2026

Industry

Healthcare Equipment and Supplies

Sector

Health Care

Employees

16

CEO

Roger J. Dumoulin-White

Website

www.theralase.com

Headquarters

Toronto, ON M4B 3G4, CA

TLTFF Financials

Key Financial Metrics (TTM)

Gross Margin

44.21%

Operating Margin

-474.33%

Net Income Margin

-472.48%

Return on Equity

-130.04%

Return on Capital

-186.74%

Return on Assets

-46.66%

Earnings Yield

-7.07%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$45.24MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

310.48M

Volume

178.56K

Avg. Volume

139.55K

Financials (TTM)

Gross Profit

CA$465.86K

Operating Income

-CA$3.81M

EBITDA

-CA$3.51M

Operating Cash Flow

-CA$3.39M

Capital Expenditure

CA$21.44K

Free Cash Flow

-CA$3.37M

Cash & ST Invst.

CA$5.26M

Total Debt

CA$148.72K

Theralase Technologies Performance Analysis

Theralase Technologies annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31CAD 874,57540.5%
20232023-12-31CAD 793,004-9.3%
20242024-12-31CAD 754,350-4.9%
20252025-12-31CAD 584,323-22.5%
Theralase Technologies sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-3027.3%
Q42025-12-31-19.2%
Q12026-03-31-41.1%
Q22026-06-3023.6%
Theralase Technologies annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31CAD -0.0212.2%
20232023-12-31CAD -0.02-20.2%
20242024-12-31CAD -0.01-16.2%
20252025-12-31CAD -0.01-9.3%
Theralase Technologies sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-30-5.3%
Q42025-12-3135.0%
Q12026-03-31-50.0%
Q22026-06-305.1%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

CA$164.29K

-25.2%

Gross Profit

CA$85.56K

-27.9%

Gross Margin

52.08%

N/A

Market Cap

$45.24MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$3.23M

N/A

Employees

14

N/A

Net Income

-CA$1.06M

-11.6%

EBITDA

-CA$1.01M

-14.3%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

CA$5.26M

+11256.4%

Total Debt

CA$148.72K

-39.3%

Accounts Receivable

CA$846.67K

+5.7%

Inventory

CA$464.14K

-12.6%

Long Term Debt

CA$36.16K

-78.3%

Short Term Debt

CA$225.16K

+188.9%

Return on Assets

-46.66%

N/A

Return on Invested Capital

-55.34%

N/A

Free Cash Flow

-CA$1.23M

-19.4%

Operating Cash Flow

-CA$1.23M

-20.3%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
BCT.TOBriaCell Therapeutics Corp.
CA$4.79-1.03%
RVX.TOResverlogix Corp.
CA$0.09+0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
SPCXSpace Exploration Technologies
$147.49+1.89%
TAT&T
$20.93-7.96%
SOXLDirexion Shares ETF Trust - Direxion Daily Semiconductor Bull 3x ETF
$83.56+1.77%
NUNu Holdings
$15.16+2.92%

Questions About TLTFF

What is the current price of Theralase Technologies?

Theralase Technologies is trading at $0.15 per share.

What is the 52-week range for Theralase Technologies?

Over the past 52 weeks, Theralase Technologies has traded between $0.10 and $0.31.

How much debt does Theralase Technologies have?

As of the most recent reporting period, Theralase Technologies reported total debt of CA$104.82K.

How much cash does Theralase Technologies have on hand?

Theralase Technologies reported CA$3.71M in cash and cash equivalents in its most recent financial results.

What is Theralase Technologies’s dividend yield?

Theralase Technologies does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services